2016 American Transplant Congress
Preemptive CMV Prophylaxis in Renal Transplant Recipients Receiving Everolimus Immunosuppression Reduces Cytomegalovirus Infection.
Surgery - Renal Transplant Unit, Università Cattolica del Sacro Cuore, Rome, Italy.
Introduction.Aim of this study was to evaluate the efficacy and safety of preemptive prophylaxis of CMV infection in kidney transplant recipients (KTx) receiving polyclonal antibodies…2016 American Transplant Congress
Differences in Reported Barriers to Immunosuppression Adherence Among a Cohort of Pediatric Renal Transplant Recipients from the United States and Canada.
Aim: The purpose of this study was to examine differences in reported barriers to immunosuppressant adherence (IA) between a cohort of pediatric renal transplant recipients…2016 American Transplant Congress
Tool to Assess Risk of Non-Adherence in Renal Transplant Candidates.
Nonadherence (NA) is likely the primary driver of late graft loss and was found to occur in 59% of renal transplant (RTx) patients at our…2016 American Transplant Congress
Pharmacist Impact on Medication Errors in a Chronic Kidney Transplant Clinic.
Medication errors are associated with increased incidence of infection, rejection, and graft loss in kidney transplant recipients. This study aims to assess the impact of…2016 American Transplant Congress
Prospective Randomized OPEN Trial Designed to Reduce the Incidence of Cytomegalovirus (CMV) Infection in DE NOVO Kidney Transplant Recipients Two-Year Results.
Transplant, Hospital Geral de Fortaleza, Fortaleza, CE, Brazil.
Introduction: CMV infection is a frequent complication following organ transplantation, and is associated with inferior long-term patient and graft survival. Here we report the results…2016 American Transplant Congress
Modification of DC Phenotype and Function via Targeted Porous Silicon Nanoparticles.
Aims: Dendritic cells (DC) are the most potent antigen-presenting cell and are fundamental in the establishment of transplant tolerance. Targeting DC via the DC-SIGN receptor…2016 American Transplant Congress
Comparison of Clinical Outcomes of Belatacept- and Tacrolimus-Based Immunosuppression in Renal Transplant Recipients.
To examine the utilization and clinical outcomes of belatacept in the real clinical setting, a retrospective cohort study was conducted using SRTR data that compared…2016 American Transplant Congress
Comparison of Efficacy and Safety of a 4-Month Post-Renal Transplant Dose Reduction of Tacrolimus.
Introduction. The aim of the study was to determine the efficacy and safety balance of 2 different doses of tacrolimus extended-release (TacER) in kidney transplant…2016 American Transplant Congress
Clinical Factors That Determine the Appropriateness of Early Steroid Withdrawal.
Early steroid withdrawal (ESW) has been a popular option for recipients with low-immunological risk. However, no quantitative tools are available to assess the risk, i.e.…2016 American Transplant Congress
Do We Need an Individually Tailored Immunosuppression Strategy for Living Donor Kidney Transplant Recipients with PreTransplant Donor Specific Antibodies? A Retrospective Analysis.
Introduction:Pre-Transplant Microbead donor HLA specific antibody(DSA) positive but cell crossmatch negative transplants are considered to be at increased immunological risk. This study aimed to address…
- « Previous Page
- 1
- …
- 109
- 110
- 111
- 112
- 113
- …
- 138
- Next Page »